FDA accepts sBLA for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy
Merck announced the FDA has accepted for review the supplemental Biologics License Application for Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for treatment of patients with advanced non-small cell lung cancer whose disease has progressed after platinum-containing chemotherapy. June 01, 2015